La catena delle opzioni mostra i dati chiave delle opzioni azionarie di ProMIS Neurosciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per ProMIS Neurosciences..

ProMIS Neurosciences (NASDAQ:PMN) Azioni, Catena delle Opzioni

ProMIS Neurosciences

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences Inc

Perfect Moment Ltd

PERSEUS MINING LTD ORD by Perseus Mining Ltd

Perseus Mining Ltd

As crypto adoption continues to grow, how individuals trade, not what they trade, has become the focus. While centralized platforms remain popular for convenience, they expose traders to more risk than is necessary.
More investors are looking for how to maintain full control of their crypto assets while minimizing exposure to third parties. One solution is necessary, decentralized crypto swaps, for example exchanging BTC for USDT. &nbsp;&nbsp;
The Problem with Centralized Swap Brokers
Most wallet-based swap interfaces, software or hardware, use centralized intermediary brokers to process transactions at present.
While the services are quick and convenient, they also expose:
• Counterparty risk, Funds are in the control of a third party temporarily during the swap.
• Privacy trade-offs, KYC requirements can force users to reveal sensitive personal information.
• Higher fees and slippage, Centralized services are more costly than decentralized alternatives.
For security-minded traders and long-term investors, these compromises are becoming ever harder to make.
Why Decentralized Swaps Offer a Better Alternative
Protocols that facilitate decentralized trading infrastructure, and wallet-to-wallet transactions without surrendering custody or personal data are the future.
Such solutions should also:
• Reduce reliance on any one central authority,
• Improve fee transparency and access to greater liquidity,
• More accurately reflect the underlying basis of crypto, decentralization and user sovereignty
Other wallet providers are beginning to recognize the value of natively embedding such decentralized protocols on their platforms, and user demand is only growing.
A Quantum Threat to Security Is on the Horizon
In addition to swap risk, another long-term problem is now taking shape, quantum computing.
Some experts, including venture capitalist Chamath Palihapitiya, are sounding the alarm that quantum developments can arrive as soon as 5 to 10 years from now, with the potential to break the encryption that safeguards today&#8217;s digital assets.
While it remains one of the most secure ways to hold crypto, exposure during swaps, especially with third parties, could be an entry point of vulnerability in the future.
Security-aware users are already adopting best practices such as:
• Never using the same exact address for multiple transactions. Use a wallet that generates a new one each time.
• Minimizing exposure to third-party custodians,
• Utilizing wallets and protocols that support decentralized infrastructure
As quantum abilities reach maturity, decentralization will not just enhance privacy and autonomy but may also turn into a default line of defense.
The Bottom Line
Integrating decentralized swap protocols into wallet ecosystems isn&#8217;t just a UX enhancement, it&#8217;s a long-term move towards privacy, affordability, and improved personal security.
For cryptocurrency traders wanting to stay ahead of both market risk and technological developments, solutions that adopt underlying decentralized principles are more important than ever.
The author has an investment in BTC.
&#x2A;&#x2A;
We at <a href="https://cryptoflowzone.com/">https://cryptoflowzone.com/</a> will continue to monitor and evaluate developments in this space to help traders make the correct choices. We also expect to pressure cold wallet providers to develop decentralized swap protocols within their solution, and offer investors a safer way of broadcast transacting in the future. Keep your eyes on the prize and Trade safe.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Opinion

Why Decentralized Swaps Are The Next Frontier For Secure Crypto Trading

Piper Sandler analyst Paul Newsome initiated coverage on Aspen Insurance Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with an Overweight rating and <a href="https://www.benzinga.com/quote/ahl/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $40</a>.
The company&#8217;s IPO took place on May 8 on the NYSE exchange and it offered shares at a price of $30 per share with an insider lock-up period of 180 days<a href="https://www.benzinga.com//node/45329236" target="_blank" rel="noreferrer noopener"> that ends on November 04, 2025</a>.
The analyst writes that AHL is a reasonably profitable specialty insurer and reinsurer and he anticipates a recently completed business transformation to facilitate future growth and improved profitability.
Newsome notes that the company underwent a significant restructuring following its acquisition by Apollo in 2019.
The analyst adds that despite divesting approximately 17 business lines across its insurance and reinsurance segments, the company has reported notable improvements in its underwriting profitability and Gross Written Premium (GWP) growth.
The analyst highlights that this transformation has reduced volatility in its underwriting performance. Also, operating Return on Equity (ROE) reached 19.4% in 2024, with a three-year average of 17.1%.
Moreover, the company has seen substantial gains in underwriting profitability, and the combined ratio improved from 98.8% in 2021 to 88.0% in 2024, according to the analyst.
Newsome says that this enhanced underwriting performance is primarily attributed to a reduction in the expense ratio, an improving underlying loss ratio, and better management of catastrophe loss risks.
Overall, the analyst believes that the company warrants a slight premium valuation compared to its reinsurance peer group, given that its specialty business accounts for approximately 60% of its gross written premiums.
The analyst estimates the EPS of $3.61 for FY25 and $4.97 for FY26.
Price Action: AHL shares are up 0.81% at $34.69  at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45196561" target="_blank" rel="noreferrer noopener">Loews Posts Mixed&nbsp;Q1&nbsp;Results: Pipeline Strength Offsets Insurance And Hotel Weakness</a></li>
</ul>
Photo: Shutterstock

Initiation

Aspen Insurance Emerges From Turnaround With Momentum: Analyst Sees More Upside Ahead

<a href="https://www.chicagofed.org/publications/speeches/2025/june-2-quad-cities-business-journal" title="https://www.chicagofed.org/publications/speeches/2025/june-2-quad-cities-business-journal">https://www.chicagofed.org/publications/speeches/2025/june-2-quad-cities-business-journal</a>

Macro Economic Events

News

Economics

Federal Reserve

Fed's Goolsbee Says Recent PCE Inflation Print May Have Been 'Last Vestige' Of Pre-Tariff Impact

Oppenheimer analyst Andreas Argyrides assumes Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) with a Outperform rating and announces Price Target of $61.

Price Target

Analyst Ratings

HRMY

Oppenheimer Assumes Harmony Biosciences Hldgs at Outperform, Announces Price Target of $61

AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and SERENA-6.
In the DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) combined with pertuzumab was evaluated as a first-line treatment for HER2-positive metastatic breast cancer, compared to a standard regimen of a taxane, trastuzumab, and pertuzumab (THP). 
Topline data <a href="https://www.benzinga.com/general/biotech/25/04/44894989/astrazeneca-daiichi-sankyos-multi-billion-dollar-cancer-drug-shows-superior-efficacy-across-broad" target="_blank" rel="noreferrer noopener">were shared in April</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/05/45168310/astrazenecas-triple-combination-therapy-breztri-hits-primary-goals-in-two-pivotal-studies-for-asthma" target="_blank" rel="noreferrer noopener">AstraZeneca&#8217;s Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma</a>
Results indicated that the Enhertu combination reduced the risk of disease progression or death by 44%. Median progression-free survival (PFS) reached 40.7 months with the Enhertu regimen versus 26.9 months for THP, a benefit observed across patient subgroups. 
Investigator-assessed median PFS was 40.7 months for the Enhertu arm and 20.7 months for THP. The confirmed objective response rate was 85.1% for the Enhertu combination and 78.6% for THP, with 58 complete responses in the Enhertu group compared to 33 with THP. 
The median duration of response was 39.2 months for the Enhertu combination and 26.4 months for THP. Overall survival data was not yet mature, though an early trend favored the Enhertu combination.
The MATTERHORN trial assessed Imfinzi (durvalumab) with standard FLOT chemotherapy as a perioperative treatment for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers, compared to chemotherapy alone. 
Topline data <a href="https://www.benzinga.com/general/biotech/25/03/44188407/astrazenecas-imfinzi-based-regimen-shows-improved-event-free-survival-in-early-stage-gastric-canc" target="_blank" rel="noreferrer noopener">were released in March</a>.
A planned interim analysis showed that the Imfinzi-based regimen led to a 29% reduction in the risk of disease progression, recurrence, or death. 
Median event-free survival (EFS) was not reached in the Imfinzi arm, compared to 32.8 months in the chemotherapy-alone arm. The estimated 24-month EFS rate was 67.4% for the Imfinzi regimen and 58.5% for chemotherapy alone. 
A trend towards improved overall survival was noted for the Imfinzi-based regimen, with formal assessment to follow.
The SERENA-6 trial investigated camizestrant combined with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors developed an ESR1 mutation during first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor.
Topline data were <a href="https://www.benzinga.com/25/02/43975577/astrazenecas-investigational-cancer-drug-shows-first-line-benefit-in-combination-with-widely-cancer-medicines" target="_blank" rel="noreferrer noopener">shared in February</a>.
The trial compared switching to the camizestrant combination against continuing the AI plus CDK4/6 inhibitor. The camizestrant combination reduced the risk of disease progression or death by 56%. 
Median PFS was 16.0 months for patients who switched, versus 9.2 months for those continuing the AI combination. The median time to deterioration of global health status was 23.0 months for the camizestrant arm and 6.4 months for the AI combination arm. 
While data for time to second disease progression and overall survival were immature, a trend favored the camizestrant combination for PFS2.
<ul class="wp-block-list"></ul>
Price Action: AZN stock is trading lower by 0.95% at $72.14 at last checkMonday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" target="_blank" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a></li>
</ul>
Photo by Piotr Swat Shutterstock

Biotech

Large Cap

Health Care

General

AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO

WIIM

Meta Platforms shares are trading higher amid reports that the company is planning to fully automate making of ads using AI.

Oppenheimer analyst Andreas Argyrides assumes Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Outperform rating and lowers Price Target of $7.

AQST

Oppenheimer Assumes Aquestive Therapeutics at Outperform, Lowers Price Target of $7

Shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) are trading lower Monday as the company faces growing pressure from Chinese electric vehicle competitors, which posted strong <a href="https://www.benzinga.com/markets/eurozone/25/05/45616006/teslas-european-woes-see-no-end-april-sales-crash-49-as-rivals-race-ahead-in-ev-market">delivery numbers for May</a>.
What To Know: Tesla&#8217;s rivals, BYD, Li Auto, Nio and Xpeng, saw <a href="https://www.benzinga.com/news/topics/25/06/45716179/teslas-china-sales-slump-while-byd-and-li-auto-post-strong-gains-report">sales growth in China</a> last month. Li Auto reported a 17% month-over-month increase, delivering 40,856 vehicles. Nio followed with over 33,500 deliveries and Xpeng delivered more than 23,000 units. BYD led the group with 204,369 battery electric vehicle deliveries in May, representing a 40% year-over-year increase.
Meanwhile Tesla has battled declining sales in the region after reporting roughly 58,000 vehicle sales in China in April, including exports. The company&#8217;s sales in the first eight weeks of second quarter have declined 23% year-over-year, suggesting continued softness in its second-largest market. Despite improving registration numbers in May — over 11,000 units registered in China for two consecutive weeks — the broader trend remains negative.
Tesla&#8217;s challenges extend beyond China. In Europe, the company posted a steep 49% drop in sales for April. For the first time, BYD surpassed Tesla in the region, signaling a significant shift in EV market dynamics.
Investors are watching closely as Tesla approaches its June 12 Robotaxi unveiling in Austin, a potential catalyst for the EV stock. 
Tesla CEO Elon Musk said last month that all that matters for the company long term are autonomy and the company's Optimus bots, which are expected to &#8220;overwhelmingly dominate the future financial success of the company.&#8221;
Analysts remain cautiously optimistic given Tesla&#8217;s advancements in Full Self-Driving (FSD) technology. However, questions linger about the company&#8217;s ability to maintain competitive footing amid rising global competition and aggressive pricing strategies, especially in China.
Despite the concerns about sales, Tesla shares have climbed about 20% over the past month as Musk&#8217;s time as a <a href="https://www.benzinga.com/25/05/45668119/tesla-rides-a-bullish-wave-as-byd-slashes-prices-whos-really-winning-the-ev-war" target="_blank" rel="noreferrer noopener">special government employee</a> comes to a close. Musk joined the Trump administration earlier this year to take a lead role at the Department of Government Efficiency, or DOGE. He announced that he was <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45672177/whats-going-on-with-tesla-stock-thursday">officially stepping away</a> from the position last week.
TSLA Price Action: Tesla shares were down 2.59% at $337.47 at the time of publication Monday, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation </a></li>
</ul>
Image via Shutterstock.

Movers

TSLA

Tesla Stock Is Trading Lower Today: What's Going On?

Gold is trading higher amid dollar weakness and trade policy uncertainty.

Fed's Goolsbee Says Still Think Underneath All The Tariff 'Dirt In The Air,' Rates Can Come Down Over 12-18 Months; Still Think If We Can Get Past This Bumpy Period, Dual Mandate Looks Pretty Good; A Little Gun-Shy About Arguing That Tariffs Will Have A Transitory Effect On Inflation

UBS Group expressed optimism <a href="https://www.benzinga.com/topic/chinese-stocks" target="_blank" rel="noreferrer noopener">about Chinese stocks</a>, citing the recent tariff pause with the U.S., potential stimulus measures from Beijing and attractive low valuations as key drivers.
UBS&#8217; stance coincided with a market sell-off in U.S. equities amid trade tensions, SCMP <a href="https://www.scmp.com/business/banking-finance/article/3312525/ubs-upbeat-china-stocks-citing-tariff-pause-us-and-potential-beijing-stimulus" target="_blank" rel="noreferrer noopener">reported</a> on Monday.
Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) is considered a tech barometer of China. Other significant U.S.-listed Chinese stocks included Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), JD.Com, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), and PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>).
Also Read: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45703311/us-listed-chinese-stocks-drop-after-trump-renews-trade-tensions" target="_blank" rel="noreferrer noopener">US Listed Chinese Stocks Drop After Trump Renews Trade Tensions</a>
Neil Hosie of UBS said Beijing&#8217;s economic policy measures in September and the emergence of artificial intelligence start-up DeepSeek&#8217;s affordable models sparked global investor interest in China equities, slowly translating into more significant fund flows.
Hosie said a 90-day tariff truce and Beijing&#8217;s hopes for domestic stimulus have translated into higher inflows into China&#8217;s markets.
Additionally, Hosie said Hong Kong&#8217;s resurgent initial public offering (IPO) market was a positive driver.
Meanwhile, Hosie said U.S. stocks were overvalued, citing the Nasdaq&#8217;s P/E of 31.70x, compared to Hong Kong&#8217;s benchmark Hang Seng Index at 10.86x and Shanghai&#8217;s main board at 15.60x, as per Bloomberg data.
Mainland Chinese households held 160 trillion yuan ($22 trillion) in cash, mostly invested in bank time deposits and about a third of it could flow into stock markets in Hong Kong as lower interest rates drive demand for riskier assets, SCMP <a href="https://www.scmp.com/business/china-business/article/3312751/chinese-households-set-buy-another-us100-billion-hong-kong-stocks-hsbc-says" target="_blank" rel="noreferrer noopener">reported</a> on Monday, citing HSBC.
Herald van der Linde, head of HSBC Asia-Pacific equity research, told SCMP that close to 50 trillion yuan, deemed excess savings over the COVID-19 pandemic years, will find their way back into local and offshore equity markets.
HSBC said Chinese investors channeled $80 billion in net inflows into Hong Kong stocks through Stock Connect&#8217;s southbound channel in 2025. At the current rate, they could funnel more excess savings to drive purchases to $180 billion by the end of the year.
HSBC said most of the cash flowing into Hong Kong&#8217;s stock market had gone into high-growth sectors such as internet firms, electric vehicle (EV) makers, and other high-yielding companies like Tencent Holdings and Alibaba.
BABA Price Actions: BABA stock is up 0.76% at $114.70 at publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/05/45692725/alibaba-and-baidu-turn-to-chinese-ai-chips-as-us-sanctions-squeeze-nvidia-supply" target="_blank" rel="noreferrer noopener">Alibaba And Baidu Turn To Chinese AI Chips As US Sanctions Squeeze Nvidia Supply</a></li>
</ul>
Photo: Shutterstock

Trading Ideas

BABA

BIDU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TCEHY

China Stocks Get Boost As UBS, HSBC Cite Stimulus Hopes, Tariff Truce, Low Valuations

AVGO

Broadcom shares are trading higher after the company announced the launch of the latest enhancements to VMware Tanzu CloudHealth.

Oppenheimer analyst Andreas Argyrides assumes Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Outperform rating and announces Price Target of $19.

ABEO

Oppenheimer Assumes Abeona Therapeutics at Outperform, Announces Price Target of $19

ATLN

Atlantic International Appoints Matt Evelt As COO, Effective Immediately

On August 15, 2025, Gray Media's local television station WANF will end its 31-year affiliation with the CBS Network to begin a new chapter as an independent television station. Going forward, WANF will leverage its successful local news operation, complete control of its daily program schedule, and the resources of the locally based Gray Media to better serve the local community with on-air and online content throughout the day that is more responsive to the growing Atlanta metropolis.

Gray Media's Local Television Station WANF To End 31-Year Affiliation With CBS Network On August 15, 2025 To Begin As Independent Television Station

<h3>Gainers</h3>
<ul>
<li>Classover Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>) stock moved upwards by 30.1% to $3.46 during Monday's regular session. The company's market cap stands at $81.9 million. </li>
<li>United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) shares moved upwards by 17.88% to $3.56. The market value of their outstanding shares is at $208.6 million. </li>
<li>Perfect Moment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) shares moved upwards by 17.18% to $0.75. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares increased by 16.99% to $1.79. The market value of their outstanding shares is at $512.2 million. </li>
<li>Red Robin Gourmet Burgers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) shares rose 16.86% to $5.96. The company's market cap stands at $105.7 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) stock increased by 13.72% to $1.16. The market value of their outstanding shares is at $123.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock decreased by 38.1% to $47.5 during Monday's regular session. The company's market cap stands at $33.1 million. </li>
<li>High Roller Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ROLR#AMEX">ROLR</a>) stock decreased by 25.01% to $3.27. The market value of their outstanding shares is at $27.5 million. </li>
<li>ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) stock declined by 17.02% to $6.8. The company's market cap stands at $181.5 million. </li>
<li>Allied Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGAE#NASDAQ">AGAE</a>) stock fell 15.62% to $2.54. The company's market cap stands at $112.0 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGP#NASDAQ">QVCGP</a>) stock declined by 12.88% to $4.93. </li>
<li>LiveWire Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NYSE">LVWR</a>) shares declined by 12.45% to $3.94. The market value of their outstanding shares is at $802.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGAE

CHGG

KIDZ

LOGC

LVWR

NWTN

PMNT

QVCGP

ROLR

RRGB

SBET

12 Consumer Discretionary Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) stock rose 376.8% to $23.5 during Monday's regular session. The market value of their outstanding shares is at $31.1 million. </li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) stock increased by 64.08% to $31.09. The company's market cap stands at $1.9 billion. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock rose 59.82% to $1.79. The company's market cap stands at $25.6 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares rose 58.0% to $0.95. The company's market cap stands at $74.1 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock moved upwards by 56.58% to $0.46. The company's market cap stands at $5.4 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 40.92% to $0.4. The company's market cap stands at $2.3 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock declined by 31.2% to $0.74 during Monday's regular session. The company's market cap stands at $38.1 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock declined by 27.47% to $4.41. The company's market cap stands at $82.8 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 19.24% to $4.24. The market value of their outstanding shares is at $15.7 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares decreased by 18.82% to $6.11. The company's market cap stands at $335.4 million. </li>
<li>TherapeuticsMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXMD#NASDAQ">TXMD</a>) stock declined by 17.81% to $1.2. The market value of their outstanding shares is at $13.8 million. </li>
<li>Olema Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) stock fell 16.1% to $4.43. The market value of their outstanding shares is at $303.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLRX

BMGL

HYPR

LYRA

MODV

OLMA

PCSA

PSTV

TXMD

VERA

VSTM

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) stock increased by 103.4% to $2.38 during Monday's regular session. The company's market cap stands at $26.1 million. </li>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) stock rose 72.27% to $3.79. The company's market cap stands at $30.1 million. </li>
<li>Lavoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) stock rose 61.15% to $4.19. The company's market cap stands at $488.5 million. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) shares increased by 45.36% to $0.79. The company's market cap stands at $7.5 million. </li>
<li>AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares moved upwards by 31.62% to $1.04. The company's market cap stands at $14.4 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock increased by 29.5% to $0.56. The company's market cap stands at $81.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock fell 22.3% to $2.4 during Monday's regular session. The market value of their outstanding shares is at $54.7 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) stock fell 19.41% to $1.37. The company's market cap stands at $16.5 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares decreased by 15.74% to $0.24. The company's market cap stands at $55.1 million. </li>
<li>Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) shares declined by 13.24% to $100.25. The company's market cap stands at $4.7 billion. As per the press release, Q1 earnings came out today. </li>
<li>Huachen AI Parking Mgmt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAI#NASDAQ">HCAI</a>) shares declined by 10.52% to $5.7. The market value of their outstanding shares is at $192.2 million. </li>
<li>Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) shares decreased by 9.0% to $5.26. The company's market cap stands at $69.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HCAI

HKPD

LNZA

LVRO

SAIC

SCWO

UAVS

VATE

ZONE

12 Industrials Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) stock increased by 46.4% to $10.0 during Monday's regular session. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares increased by 36.37% to $0.38. The company's market cap stands at $15.7 million. </li>
<li>Alpha Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) stock rose 33.07% to $35.0. The company's market cap stands at $576.1 million. </li>
<li>CISO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) shares moved upwards by 24.69% to $1.01. The market value of their outstanding shares is at $32.3 million. </li>
<li>WidePoint (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WYY#AMEX">WYY</a>) stock rose 20.93% to $3.64. The company's market cap stands at $35.6 million. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) stock moved upwards by 20.55% to $0.66. The market value of their outstanding shares is at $4.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock decreased by 12.3% to $1.28 during Monday's regular session. The company's market cap stands at $12.7 million. </li>
<li>SemiLEDs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEDS#NASDAQ">LEDS</a>) shares fell 12.09% to $2.62. The company's market cap stands at $18.8 million. </li>
<li>Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) shares decreased by 11.54% to $1.91. The market value of their outstanding shares is at $54.4 million. </li>
<li>Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) stock declined by 11.05% to $0.85. The company's market cap stands at $51.3 million. </li>
<li>Pony AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) shares fell 10.86% to $17.17. The market value of their outstanding shares is at $6.1 billion. </li>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) shares declined by 10.82% to $1.07. The market value of their outstanding shares is at $77.6 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLD

ATGL

BNAI

CISO

GRYP

LEDS

MLGO

MOVE

PONY

UPLD

12 Information Technology Stocks Moving In Monday's Intraday Session

CBS, a subsidiary of Paramount Global, and Gray Media (&quot;Gray&quot;) announced today that they have entered into an agreement that renews 52 of Gray&#39;s existing 53 CBS network affiliations. As part of the agreement, the renewing CBS affiliates will continue to be available locally to subscribers on Paramount+ and widely distributed across all traditional and virtual MVPD platforms. Effective August 16, 2025, Gray&#39;s Atlanta station WANF will cease its affiliation with the CBS Network and thereafter operate an independent television station hyper-focused on the Atlanta market.

PARA

Paramount Global's CBS And Gray Media Renew Affiliation Agreements For 52 Of Gray's Existing 53 CBS Network Affiliations

Press Releases

ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease

ProMIS Neurosciences Issues Letter to Shareholders

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

Maxim Group

Guggenheim

BTIG

Comments

ProMIS Neurosciences

ProMIS Neurosciences (PMN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO